🇺🇸 FDA
Pipeline program

Radotinib HCl, Placebo for Radotinib HCl

RT51EP1902

Phase 2 small_molecule active

Quick answer

Radotinib HCl, Placebo for Radotinib HCl for Treatment of Parkinson’s disease (PD) is a Phase 2 program (small_molecule) at Pharm Research Associates (UK) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharm Research Associates (UK) Limited
Indication
Treatment of Parkinson’s disease (PD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials